A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.
Objective: To evaluate the safety and tolerability of repurposing Ambroxol as a disease modifying treatment for Parkinson’s Disease Dementia (PDD). Background: Carrying a mutation in…Blood derived α-synuclein seeding in the course of Parkinson’s Disease
Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients with different disease durations…RT-QuIC for detection of pathological α-synuclein in the olfactory mucosa and CSF of Parkinson’s disease patients
Objective: To investigate the proficiency of RT-QuIC in detecting the presence of misfolded α-synuclein (α-syn) on the olfactory mucosa (OM) and CSF of patients with…Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia
Objective: To understand molecular heterogeneity among Parkinson’s disease (PD) patients, and controls based on α-synuclein seed amplification assay (SAA) results. Background: α-synuclein seed amplification assay…Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease
Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy
Objective: IkT-148009 is a potent selective inhibitor of non-receptor Abelson Tyrosine Kinases (c-Abl kinases). Our recent analysis of post-mortem brain tissue from patients with Multiple…Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson’s disorder
Objective: Identification and evaluation of the potential of a novel NLR family pyrin domain containing 3 (NLRP3) inflammasome inhibitor (ZYIL1) as a Parkinson’s disease (PD)…Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report
Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…Gray matter volume of proposed brain-first and body-first Parkinson’s disease subtypes
Objective: The aim of this study was to test if markers of the brain-first Parkinson’s disease (PD) subtype are associated with a greater or more…DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease
Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 51
- Next Page »